Elevated Heart Rate Following Heart Transplantation Is Associated With Increased Graft Vasculopathy and Mortality.


Journal

Journal of cardiac failure
ISSN: 1532-8414
Titre abrégé: J Card Fail
Pays: United States
ID NLM: 9442138

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 26 09 2018
revised: 14 12 2018
accepted: 18 01 2019
pubmed: 28 1 2019
medline: 10 3 2020
entrez: 28 1 2019
Statut: ppublish

Résumé

The effect of elevated heart rate (HR) on outcomes after heart transplantation (HT) has not been well established. The aim of this study was to assess predictors of elevated HR following HT and its impact on outcomes. We retrospectively evaluated 394 patients who underwent HT at 2 academic medical centers from 2005 to 2016. Patients were divided into 2 groups based on HR 1 year after HT: HR ≥95 beats/min (n = 162; 41%) and HR <95 beats/min (n = 232; 59%). Median follow-up time was 6.6 (interquartile range [IQR] 2.2-7.5) years. HR ≥95 beats/min 1 year after HT was associated with younger donor age, whereas HR <95 beats/min was associated with heavy donor alcohol use and African-American recipient race. Left ventricular (LV) end-diastolic dimension, mass, and ejection fraction were lower and E/E' higher in the HR ≥95 group at the time of the last follow up. HR ≥95 beats/min at 1 year after HT was independently associated with the development of cardiac allograft vasculopathy and increased mortality. HR ≥95 beats/min 1 year after HT is associated with a reduction in LV size and function, increased incidence of cardiac allograft vasculopathy, and reduced survival. Studies investigating the effect of medical HR reduction on post-HT outcomes are warranted.

Sections du résumé

BACKGROUND BACKGROUND
The effect of elevated heart rate (HR) on outcomes after heart transplantation (HT) has not been well established. The aim of this study was to assess predictors of elevated HR following HT and its impact on outcomes.
METHODS AND RESULTS RESULTS
We retrospectively evaluated 394 patients who underwent HT at 2 academic medical centers from 2005 to 2016. Patients were divided into 2 groups based on HR 1 year after HT: HR ≥95 beats/min (n = 162; 41%) and HR <95 beats/min (n = 232; 59%). Median follow-up time was 6.6 (interquartile range [IQR] 2.2-7.5) years. HR ≥95 beats/min 1 year after HT was associated with younger donor age, whereas HR <95 beats/min was associated with heavy donor alcohol use and African-American recipient race. Left ventricular (LV) end-diastolic dimension, mass, and ejection fraction were lower and E/E' higher in the HR ≥95 group at the time of the last follow up. HR ≥95 beats/min at 1 year after HT was independently associated with the development of cardiac allograft vasculopathy and increased mortality.
CONCLUSIONS CONCLUSIONS
HR ≥95 beats/min 1 year after HT is associated with a reduction in LV size and function, increased incidence of cardiac allograft vasculopathy, and reduced survival. Studies investigating the effect of medical HR reduction on post-HT outcomes are warranted.

Identifiants

pubmed: 30685400
pii: S1071-9164(18)31021-2
doi: 10.1016/j.cardfail.2019.01.009
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

249-256

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Max Liebo (M)

Loyola University Medical Center, Maywood, Illinios.

Joshua Newman (J)

Loyola University Medical Center, Maywood, Illinios.

Anjali Joshi (A)

Loyola University Medical Center, Maywood, Illinios.

Brian D Lowes (BD)

University of Nebraska Medical Center, Omaha, Nebraska.

Yael Peled-Potashnik (Y)

The Olga and Lev Leviev Heart Center, Sheba Medical Center, Ramat Gan, Israel.

Haseeb Ilias Basha (HI)

Loyola University Medical Center, Maywood, Illinios.

Ronald Zolty (R)

University of Nebraska Medical Center, Omaha, Nebraska.

John Y Um (JY)

University of Nebraska Medical Center, Omaha, Nebraska.

Edwin McGee (E)

Loyola University Medical Center, Maywood, Illinios.

Alain Heroux (A)

Loyola University Medical Center, Maywood, Illinios.

Eugenia Raichlin (E)

Loyola University Medical Center, Maywood, Illinios; University of Nebraska Medical Center, Omaha, Nebraska. Electronic address: eugenia.raichlin@lumc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH